Ardhendu Kumar Maji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ardhendu Kumar Maji has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Dilip K. Bera
Deparment of Microbiology, Calcutta School of Tropical Medicine
4 shared publicationsKrishnangshu Ray
Calcutta School of Tropical Medicine, Kolkata, India
4 shared publicationsPabitra Saha
Calcutta School of Tropical Medicine, Kolkata, India
4 shared publicationsPratip K. Kundu
Deparment of Microbiology, Calcutta School of Tropical Medicine
4 shared publicationsAsit Biswas
Department of Health and Family Welfare, Government of West Bengal, Swasthya Bhawan, Salt Lake City, Kolkata, India
3 shared publicationsShrabanee Mullick
Calcutta School of Tropical Medicine, Kolkata, India
3 shared publications
Latest Publications
- 1 January 2015
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 68 (4) , 321-323
Impact of Artemisinin-Based Combination Therapy on Falciparum Malaria in Urban Kolkata: A Clinic-Based Report
In India combination of artesunate + sulphadoxine-pyrimethamine has been implemented for uncomplicated falciparum malaria since 2010. We observed the impact of this intervention in urban Kolkata by analyzing data of Malaria Clinic from 2001 to 2013. In Kolkata P. vivax is perennial whereas P. falciparum infection is seasonal. Before ACT implementation P. falciparum percentage was as high as 50% which steadily decreased during four successive years post intervention. No change was observed in case of vivax cases. ACT is probably an effective measure in reducing falciparum malaria cases. Any artemisinin derivative combination should be explored in vivax malaria to reduce the overall malaria burden.
- 1 January 2015
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 68 (4) , 321-323
Impact of Artemisinin-Based Combination Therapy on Falciparum Malaria in Urban Kolkata: A Clinic-Based Report
In India combination of artesunate + sulphadoxine-pyrimethamine has been implemented for uncomplicated falciparum malaria since 2010. We observed the impact of this intervention in urban Kolkata by analyzing data of Malaria Clinic from 2001 to 2013. In Kolkata P. vivax is perennial whereas P. falciparum infection is seasonal. Before ACT implementation P. falciparum percentage was as high as 50% which steadily decreased during four successive years post intervention. No change was observed in case of vivax cases. ACT is probably an effective measure in reducing falciparum malaria cases. Any artemisinin derivative combination should be explored in vivax malaria to reduce the overall malaria burden.
- 1 May 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (5) , 2511-2517
Comparative Efficacies of Artemisinin Combination Therapies in Plasmodium falciparum Malaria and Polymorphism of pfATPase6 , pfcrt , pfdhfr , and pfdhps Genes in Tea Gardens of Jalpaiguri District, India
In India, chloroquine has been replaced by a combination of artesunate and sulfadoxine-pyrimethamine (AS-SP) for uncomplicated P. falciparum malaria. Other available combinations, artemether-lumefantrine (AM-LF) and artesunate-mefloquine (AS-MQ), not included in the national program, are widely used by private practitioners. Little is known about the therapeutic efficacy of these artemisinin combinations and the prevalence of molecular markers associated with antimalarial drug resistance. A total of 157 patients with P. falciparum monoinfection were recruited and randomized into three study groups (AS-SP, AM-LF, and AS-MQ). All patients were followed up for 42 days to study the clinical and parasitological responses according to the WHO protocol (2009). We assessed the polymorphism of the pfATPase6 , pfcrt , pfdhfr , and pfdhps genes by the DNA-sequencing method. The PCR-corrected therapeutic efficacies of AS-SP, AM-LF, and AS-MQ were 90.6% (95% confidence interval [CI], 0.793 to 0.969), 95.9% (95% CI, 0.860 to 0.995), and 100% (95% CI, 0.927 to 1.00), respectively. No specific mutational pattern was observed in the pfATPase6 gene. All isolates had a K76T mutation in the pfcrt gene. In the pfdhfr-pfdhps genotype, quadruple mutation was frequent, and quintuple mutation was documented in 6.3% of P. falciparum isolates. The significant failure rate of AS-SP (9.5%), although within the limit (10%) for drug policy change, was due to SP failure because of prevailing mutations in pfdhfr , I 51 R 59 N 108 , with pfdhps , G 437 and/or E 540 . The efficacy of this ACT needs periodic monitoring. Artemether-lumefantrine and artesunate-mefloquine are effective alternatives to the artesunate-sulfadoxine-pyrimethamine combination.
- 1 May 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (5) , 2511-2517
Comparative Efficacies of Artemisinin Combination Therapies in Plasmodium falciparum Malaria and Polymorphism of pfATPase6 , pfcrt , pfdhfr , and pfdhps Genes in Tea Gardens of Jalpaiguri District, India
In India, chloroquine has been replaced by a combination of artesunate and sulfadoxine-pyrimethamine (AS-SP) for uncomplicated P. falciparum malaria. Other available combinations, artemether-lumefantrine (AM-LF) and artesunate-mefloquine (AS-MQ), not included in the national program, are widely used by private practitioners. Little is known about the therapeutic efficacy of these artemisinin combinations and the prevalence of molecular markers associated with antimalarial drug resistance. A total of 157 patients with P. falciparum monoinfection were recruited and randomized into three study groups (AS-SP, AM-LF, and AS-MQ). All patients were followed up for 42 days to study the clinical and parasitological responses according to the WHO protocol (2009). We assessed the polymorphism of the pfATPase6 , pfcrt , pfdhfr , and pfdhps genes by the DNA-sequencing method. The PCR-corrected therapeutic efficacies of AS-SP, AM-LF, and AS-MQ were 90.6% (95% confidence interval [CI], 0.793 to 0.969), 95.9% (95% CI, 0.860 to 0.995), and 100% (95% CI, 0.927 to 1.00), respectively. No specific mutational pattern was observed in the pfATPase6 gene. All isolates had a K76T mutation in the pfcrt gene. In the pfdhfr-pfdhps genotype, quadruple mutation was frequent, and quintuple mutation was documented in 6.3% of P. falciparum isolates. The significant failure rate of AS-SP (9.5%), although within the limit (10%) for drug policy change, was due to SP failure because of prevailing mutations in pfdhfr , I 51 R 59 N 108 , with pfdhps , G 437 and/or E 540 . The efficacy of this ACT needs periodic monitoring. Artemether-lumefantrine and artesunate-mefloquine are effective alternatives to the artesunate-sulfadoxine-pyrimethamine combination.
- Open Access
- 1 January 2012
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 44 (4) , 500-3
Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
Context: Visceral leishmaniasis (VL), also known as Kala-azar (KA) is a public health problem of tropical and subtropical countries, which infects about 12 million people annually, out of which about 1.5 million are new cases. India contributes a major share of the global burden of VL. For many years leishmaniasis has been treated with pentavalent antimonials. Antimony resistance is a problem in India and in other different geographic areas of the world. Amphotericin B deoxycholate and pentamidine isethionate are effective by parenteral administration and associated with toxicities. The quest for an effective, orally administered, non-toxic and less expensive alternative resulted in the identification of miltefosine (hexadecylphosphocholine). In India, therapeutic efficacy of miltefosine in VL was assessed by many groups of scientists, mainly from Bihar and Uttar Pradesh. No such data is available from West Bengal. Aims: The present study was designed to observe the efficacy of miltefosine in VL in rural West Bengal. Materials and Methods: A total of 71 parasitologically proven VL patients participated in the study who received miltefosine in accordance with the National Vector Born Disease Control Programme (NVBDCP) of India and were followed up for the following one year. Results: The overall efficacy of the drug was 93% and no significant adverse side effects were observed during the study period. Conclusions: The study concludes that miltefosine is effective, well tolerated, and easily administrable drug in the treatment of visceral leishmaniasis at the field levels.
- 1 January 2012
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 44 (4) , 500-3
Open AccessEfficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
Context: Visceral leishmaniasis (VL), also known as Kala-azar (KA) is a public health problem of tropical and subtropical countries, which infects about 12 million people annually, out of which about 1.5 million are new cases. India contributes a major share of the global burden of VL. For many years leishmaniasis has been treated with pentavalent antimonials. Antimony resistance is a problem in India and in other different geographic areas of the world. Amphotericin B deoxycholate and pentamidine isethionate are effective by parenteral administration and associated with toxicities. The quest for an effective, orally administered, non-toxic and less expensive alternative resulted in the identification of miltefosine (hexadecylphosphocholine). In India, therapeutic efficacy of miltefosine in VL was assessed by many groups of scientists, mainly from Bihar and Uttar Pradesh. No such data is available from West Bengal. Aims: The present study was designed to observe the efficacy of miltefosine in VL in rural West Bengal. Materials and Methods: A total of 71 parasitologically proven VL patients participated in the study who received miltefosine in accordance with the National Vector Born Disease Control Programme (NVBDCP) of India and were followed up for the following one year. Results: The overall efficacy of the drug was 93% and no significant adverse side effects were observed during the study period. Conclusions: The study concludes that miltefosine is effective, well tolerated, and easily administrable drug in the treatment of visceral leishmaniasis at the field levels.
- Open Access
- 30 December 2011
- Published by Bioinfo Publications in International Journal of Parasitology Research
- Vol. 3 (2) , 39-47
DISTRIBUTION OF PFCRT HAPLOTYPES AND IN-VIVO EFFICACY OF CHLOROQUINE IN TREATMENT OF UNCOMPLICATED P. FALCIPARUM MALARIA BEFORE DEPLOYMENT OF ARTEMISININ COMBINATION THERAPIES IN URBAN POPULATION OF KOLKATA, INDIA
A total of 101 P. falciparum positive patients were enrolled from urban population of Kolkata, India to determine the therapeutic efficacy of chloroquine as per 28 days follow-up schedule of WHO, 2003. All parasite strains were analyzed for P. falciparum chloroquine resistance transporter (pfcrt) haplotypes using DNA sequencing methodology. The PCR corrected chloroquine resistant P. falciparum was very high (76.3%, 95% CI 0.642-0.832) of which early treatment failure was (10%), and late treatment failure was (66.3%). K76T mutation was found in all parasite strains irrespective of therapeutic outcomes. Both the Venezuelan (SVMNT) and Southeast Asian (CVIET) haplotypes were prevalent in the study population with predominance of South East Asian haplotype (87.1%). The present study showed that incidence of CQ resistant P. falciparum malaria in Kolkata was very high and well above the WHO recommended cutoff level for change of drug policy. Recently introduced Artimisinine Combination Therapy by the Government of India to treat all P. falciparum cases is an appropriate step.
- 30 December 2011
- Published by Bioinfo Publications in International Journal of Parasitology Research
- Vol. 3 (2) , 39-47
Open AccessDISTRIBUTION OF PFCRT HAPLOTYPES AND IN-VIVO EFFICACY OF CHLOROQUINE IN TREATMENT OF UNCOMPLICATED P. FALCIPARUM MALARIA BEFORE DEPLOYMENT OF ARTEMISININ COMBINATION THERAPIES IN URBAN POPULATION OF KOLKATA, INDIA
A total of 101 P. falciparum positive patients were enrolled from urban population of Kolkata, India to determine the therapeutic efficacy of chloroquine as per 28 days follow-up schedule of WHO, 2003. All parasite strains were analyzed for P. falciparum chloroquine resistance transporter (pfcrt) haplotypes using DNA sequencing methodology. The PCR corrected chloroquine resistant P. falciparum was very high (76.3%, 95% CI 0.642-0.832) of which early treatment failure was (10%), and late treatment failure was (66.3%). K76T mutation was found in all parasite strains irrespective of therapeutic outcomes. Both the Venezuelan (SVMNT) and Southeast Asian (CVIET) haplotypes were prevalent in the study population with predominance of South East Asian haplotype (87.1%). The present study showed that incidence of CQ resistant P. falciparum malaria in Kolkata was very high and well above the WHO recommended cutoff level for change of drug policy. Recently introduced Artimisinine Combination Therapy by the Government of India to treat all P. falciparum cases is an appropriate step.
- Open Access
- 12 May 2011
- Published by Wiley in Tropical Medicine & International Health
- Vol. 16 (8) , 929-935
Efficacy of Chloroquine and Sulphadoxine‐Pyrimethamine either alone or in combination before introduction of ACT as first‐line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India
Objective In India, till recently, Chloroquine was used as first‐line therapy in areas with Chloroquine sensitive Plasmodium falciparum malaria cases. The National Vector Borne Disease Control Programme (NVBDCP) has introduced artemisinin combination therapy (ACT) as first‐line option to treat all P. falciparum cases in the country. This study was carried out to ascertain the efficacy of Chloroquine and Sulphadoxine‐Pyrimethamine, either alone or in combination, before the launch of ACT by NVBDCP. Methods A total of 300 P. falciparum malaria cases were enrolled randomly in three study arms, Chloroquine (CQ), Sulphadoxine‐Pyrimethamine (SP) and Chloroquine plus Sulphadoxine‐Pyrimethamine (CQ + SP). All patients were followed up for 28 days as per WHO (Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria, Geneva, 2003) Protocol. Paired blood samples of treatment failure cases were collected and subjected to MSP 1, MSP 2 and GLURP genotyping for differentiation between re‐infection and recrudescence. The data were analysed by Kaplan–Meier survival curve according to WHO standard procedures. Results The overall failure rate including both early treatment failure (ETF) and late treatment failure (LTF) of CQ, SP and CQ + SP were 61%, 14% and 8%, respectively, in the study area. Of 60 recurrent malaria cases, genotyping was successful in 49 cases, revealing that most of the (46/49; 94%) cases of recurrent malaria were due to recrudescence. Conclusion In Jalpaiguri District the overall failure rate of CQ was 61% and of SP 14%, which was well above the WHO recommended cut‐off threshold level (10%) for change of drug policy.
- 12 May 2011
- Published by Wiley in Tropical Medicine & International Health
- Vol. 16 (8) , 929-935
Open AccessEfficacy of Chloroquine and Sulphadoxine‐Pyrimethamine either alone or in combination before introduction of ACT as first‐line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India
Objective In India, till recently, Chloroquine was used as first‐line therapy in areas with Chloroquine sensitive Plasmodium falciparum malaria cases. The National Vector Borne Disease Control Programme (NVBDCP) has introduced artemisinin combination therapy (ACT) as first‐line option to treat all P. falciparum cases in the country. This study was carried out to ascertain the efficacy of Chloroquine and Sulphadoxine‐Pyrimethamine, either alone or in combination, before the launch of ACT by NVBDCP. Methods A total of 300 P. falciparum malaria cases were enrolled randomly in three study arms, Chloroquine (CQ), Sulphadoxine‐Pyrimethamine (SP) and Chloroquine plus Sulphadoxine‐Pyrimethamine (CQ + SP). All patients were followed up for 28 days as per WHO (Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria, Geneva, 2003) Protocol. Paired blood samples of treatment failure cases were collected and subjected to MSP 1, MSP 2 and GLURP genotyping for differentiation between re‐infection and recrudescence. The data were analysed by Kaplan–Meier survival curve according to WHO standard procedures. Results The overall failure rate including both early treatment failure (ETF) and late treatment failure (LTF) of CQ, SP and CQ + SP were 61%, 14% and 8%, respectively, in the study area. Of 60 recurrent malaria cases, genotyping was successful in 49 cases, revealing that most of the (46/49; 94%) cases of recurrent malaria were due to recrudescence. Conclusion In Jalpaiguri District the overall failure rate of CQ was 61% and of SP 14%, which was well above the WHO recommended cut‐off threshold level (10%) for change of drug policy.